Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC009
- Development stage
- Phase 2
- Lead developer
- Beijing Houcheng Medical Technology
- Administration
- Oral
01
Overview
HC009 is an investigational orally administered traditional Chinese medicine and natural-drug preparation being developed by Beijing Houcheng Medical Technology for diminished ovarian reserve with the traditional Chinese medicine pattern of kidney deficiency and liver stagnation. In China trial CTR20254996, HC009 oral solution is being evaluated in a randomized, double-blind, dose-exploration, parallel-controlled, multicenter Phase II study assessing efficacy, safety, and optimal dose. Public trial information does not disclose its active constituents, molecular targets, or molecular mechanism of action. ([chinadrugtrials.org.cn](https://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml?keywords=CTR20254996))
- Other names
- HC-009 oral solutionHC009 oral solutionHC 009 oral solutionHC009合剂
Beyond the preview
Go deeper on HC009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC009.